Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Real-world treatment patterns for patients with metastatic head and neck squamous cell carcinoma treated with immuno-oncology therapy.

Mehra R, Huang H, Seal B, Tse J, Shenolikar RA, Burudpakdee C.

Head Neck. 2020 Mar 9. doi: 10.1002/hed.26126. [Epub ahead of print]

PMID:
32149458
2.

Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder.

Seetasith A, Greene M, Hartry A, Burudpakdee C.

Clinicoecon Outcomes Res. 2019 Dec 4;11:741-755. doi: 10.2147/CEOR.S220007. eCollection 2019.

3.

Treatment patterns, adverse events, healthcare resource use and costs among commercially insured patients with mantle cell lymphoma in the United States.

Kabadi SM, Near A, Wada K, Burudpakdee C.

Cancer Med. 2019 Dec;8(17):7174-7185. doi: 10.1002/cam4.2559. Epub 2019 Oct 8.

4.

The huntingtin inclusion is a dynamic phase-separated compartment.

Aktar F, Burudpakdee C, Polanco M, Pei S, Swayne TC, Lipke PN, Emtage L.

Life Sci Alliance. 2019 Sep 16;2(5). pii: e201900489. doi: 10.26508/lsa.201900489. Print 2019 Oct.

5.

Clinical outcomes associated with pathogenic genomic instability mutations in prostate cancer: a retrospective analysis of US pharmacy and medical claims data.

Liu J, Near A, Chiarappa JA, Wada K, Tse J, Burudpakdee C, Behl A, Ranganath R, Antonarakis ES.

J Med Econ. 2019 Oct;22(10):1080-1087. doi: 10.1080/13696998.2019.1649267. Epub 2019 Aug 28.

PMID:
31352849
6.

Assessment and effect of a gap between new-onset epilepsy diagnosis and treatment in the US.

Kalilani L, Faught E, Kim H, Burudpakdee C, Seetasith A, Laranjo S, Friesen D, Haeffs K, Kiri V, Thurman DJ.

Neurology. 2019 May 7;92(19):e2197-e2208. doi: 10.1212/WNL.0000000000007448. Epub 2019 Apr 10.

7.

Comparative effectiveness of teriflunomide and dimethyl fumarate in patients with relapsing forms of MS in the retrospective real-world Teri-RADAR study.

Zivadinov R, Kresa-Reahl K, Weinstock-Guttman B, Edwards K, Burudpakdee C, Bergsland N, Dwyer MG, Khatri B, Thangavelu K, Chavin J, Mandel M, Cohan S.

J Comp Eff Res. 2019 Apr;8(5):305-316. doi: 10.2217/cer-2018-0135. Epub 2019 Feb 13.

8.

The impact of copay assistance on patient out-of-pocket costs and treatment rates with ALK inhibitors.

Seetasith A, Wong W, Tse J, Burudpakdee C.

J Med Econ. 2019 May;22(5):414-420. doi: 10.1080/13696998.2019.1580200. Epub 2019 Mar 1.

PMID:
30729850
9.

Evaluation of patient support program and adherence to long-acting injectable aripiprazole for patients utilizing injection local care centers.

Greene M, Burudpakdee C, Seetasith A, Behling M, Krasa H.

Curr Med Res Opin. 2019 Jan;35(1):97-103. doi: 10.1080/03007995.2018.1536651. Epub 2018 Nov 5.

PMID:
30322282
10.

Adherence rates and health care costs in Crohn's disease patients receiving certolizumab pegol with and without home health nurse assistance: results from a retrospective analysis of patient claims and home health nurse data.

Wolf DC, Jaganathan S, Burudpakdee C, Seetasith A, Low R, Lee E, Gucky J, Yassine M, Schwartz DA.

Patient Prefer Adherence. 2018 May 21;12:869-878. doi: 10.2147/PPA.S148777. eCollection 2018.

11.

Changes in healthcare resource use and costs associated with early versus delayed initiation of atypical antipsychotic adjunctive treatment in major depressive disorder.

Seetasith A, Greene M, Hartry A, Burudpakdee C.

J Med Econ. 2018 Sep;21(9):888-901. doi: 10.1080/13696998.2018.1484373. Epub 2018 Jun 19.

PMID:
29862860
12.

A Real-World Evidence Study Assessing the Impact of Adding the Aerobika Oscillating Positive Expiratory Pressure Device to Standard of Care Upon Healthcare Resource Utilization and Costs in Post-Operative Patients.

Burudpakdee C, Near AM, Huang H, Coppolo D, Kushnarev V, Suggett J.

Pulm Ther. 2018 Jun;4(1):87-101. doi: 10.1007/s41030-018-0055-9. Epub 2018 May 16.

13.

The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US population.

Blonde L, Burudpakdee C, Divino V, Bookhart B, Cai J, Pfeifer M, Coleman CI.

Curr Med Res Opin. 2018 Aug;34(8):1501-1511. doi: 10.1080/03007995.2018.1467887. Epub 2018 May 3.

PMID:
29671627
14.

Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer.

Burudpakdee C, Wong W, Seetasith A, Corvino FA, Yeh W, Gubens M.

Lung Cancer. 2018 May;119:103-111. doi: 10.1016/j.lungcan.2018.03.008. Epub 2018 Mar 9.

15.

A Retrospective Study of the Effectiveness of the AeroChamber Plus® Flow-Vu® Antistatic Valved Holding Chamber for Asthma Control.

Burudpakdee C, Kushnarev V, Coppolo D, Suggett JA.

Pulm Ther. 2017 Dec;3(2):283-296. doi: 10.1007/s41030-017-0047-1. Epub 2017 Jul 14.

16.

A Database Cohort Study to Assess the Risk of Angioedema Among Patients with Heart Failure Initiating Angiotensin-Converting Enzyme Inhibitors in the USA.

Do TP, Seetasith A, Belleli R, Schlienger RG, Corda S, Burudpakdee C, Streefkerk HJ, Behr S.

Am J Cardiovasc Drugs. 2018 Jun;18(3):205-211. doi: 10.1007/s40256-017-0256-x.

PMID:
29177815
17.

Adherence and persistence in patients with type 2 diabetes mellitus newly initiating canagliflozin, dapagliflozin, dpp-4s, or glp-1s in the United States.

Cai J, Divino V, Burudpakdee C.

Curr Med Res Opin. 2017 Jul;33(7):1317-1328. doi: 10.1080/03007995.2017.1320277. Epub 2017 May 8.

PMID:
28418262
18.

Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.

Burudpakdee C, Lin HM, Wang W, Seetasith A, Zhu Y, Bonthapally V, Carson KR.

J Med Econ. 2016 Oct;19(10):965-72. doi: 10.1080/13696998.2016.1187622. Epub 2016 May 26.

PMID:
27152635
19.

Impact of patient programs on adherence and persistence in inflammatory and immunologic diseases: a meta-analysis.

Burudpakdee C, Khan ZM, Gala S, Nanavaty M, Kaura S.

Patient Prefer Adherence. 2015 Mar 11;9:435-48. doi: 10.2147/PPA.S77053. eCollection 2015.

21.

A Guideline-Based Estimate of Health Care Resource Use and Cost of Metastatic Unresectable Osteosarcoma.

Cornelio N, Burudpakdee C.

Value Health. 2014 Nov;17(7):A629-30. doi: 10.1016/j.jval.2014.08.2249. Epub 2014 Oct 26. No abstract available.

22.

Predictive Modeling to Assess Predictors of Treatment Success and Failure Among Combination Statin Therapy Patients.

Nyandege A, Burudpakdee C, Philip S.

Value Health. 2014 Nov;17(7):A546. doi: 10.1016/j.jval.2014.08.1772. Epub 2014 Oct 26. No abstract available.

23.

Impact of Patient Programs On Adherence In Inflammation and Immunology: A Global Systematic Review and Meta-Analysis of Published Evidence.

Burudpakdee C, Khan ZM, Gala S, Nanavaty M, Kaura S.

Value Health. 2014 Nov;17(7):A534. doi: 10.1016/j.jval.2014.08.1704. Epub 2014 Oct 26. No abstract available.

24.

Comparison of Resource use and Health Care Costs in New Initiators of Long-Acting Injectable (Lai) and Oral Second Generation Antipsychotics.

Seetasith A, Burudpakdee C.

Value Health. 2014 Nov;17(7):A464. doi: 10.1016/j.jval.2014.08.1295. Epub 2014 Oct 26. No abstract available.

25.

The economic burden of psoriasis: a systematic literature review.

Feldman SR, Burudpakdee C, Gala S, Nanavaty M, Mallya UG.

Expert Rev Pharmacoecon Outcomes Res. 2014 Oct;14(5):685-705. doi: 10.1586/14737167.2014.933671. Epub 2014 Jul 23. Review.

PMID:
25052261
26.

Experiences and treatment patterns of hypogonadal men in a U.S. health system.

Shortridge EF, Polzer P, Donga P, Blanchette CM, Fang Y, Burudpakdee C, Carswell B.

Int J Clin Pract. 2014 Oct;68(10):1257-63. doi: 10.1111/ijcp.12418. Epub 2014 Mar 28.

PMID:
24673748
27.

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.

J Manag Care Pharm. 2013 Oct;19(8):621-30.

28.

Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.

Miller LA, Burudpakdee C, Zagar A, Bhosle M, Reaney M, Schabert VF, Bruhn D.

J Med Econ. 2012;15(4):746-57. doi: 10.3111/13696998.2012.679756. Epub 2012 Apr 3.

PMID:
22443463
29.

Economic burden of toxicities associated with metastatic colorectal cancer treatment regimens containing monoclonal antibodies.

Burudpakdee C, Zhao Z, Munakata J, Gao S, Trochlil K, Barber B.

J Med Econ. 2012;15(2):371-7. doi: 10.3111/13696998.2011.650774. Epub 2012 Jan 16.

PMID:
22181051

Supplemental Content

Loading ...
Support Center